Description
Since their clinical use initiation in the 1970’s, Fluorine-18 (F-18) radiopharmaceuticals continue to play an important role in nuclear medicine. It is therefore essential to make available broad information on practical production routes and optimal quality control for F- 18 tracers, to achieve the best possible products in high quantity and quality for clinical applications while fulfilling all regulatory requirements. This publication describes the chemical and biological properties of F-18 radiopharmaceuticals. This includes aspects relating to F-18 target production and radiofluorination methods, with focus on the applied techniques. The publication presents a disease oriented approach, describing F-18 radiopharmaceuticals, ranging from the physiological/biological aspects to dedicated radiopharmaceutical development approaches and provides readers with clear guidelines and methods for the production of F-18 radiopharmaceuticals.
More Information on reusing IAEA copyright material.
Keywords
Production, QC, Quality Control, F-18, Fluorine-18, Radiopharmaceuticals, Nuclear Medicine, Production Route, Tracer, Clinical Application, Regulatory Requirement, Chemical, Biological, Physiological, Target Production, Radiofluorination, Applied Technique, Disease Oriented Approach, Development Approach, Guideline, Method, PET, Positron Emission Tomography, Biochemistry, Medicinal Chemistry, Radiochemistry, Cyclotron, Irradiation, Target, Diagnostic, Radionuclide, Clinical Trial, ASM, Automated Synthesis Module, Fluorination, Regulatory Consideration, CRP, Coordinated Research Project, CT, Computed Tomography, MRI, Magnetic Resonance Imaging
Related publications
2024
2024
2024
2024
2024
2024
2024
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023
2023